PTC Therapeutics, Inc. (PTCT) Price Target Analysis
Updated Jul 2, 2026
Analyst Rating: Buy
Based on 26 analysts12.2% Below Target
PTCT trades 12.2% below Wall Street's consensus target of $95.83.
Current Price$85.44
Average Target$95.83
Target
Current
Low$82.00
Median$90.00
High$120.00
Analyst Target Range
Forward P/E96.4x
(High Premium)
PEG Ratio—
Implied Growth+139.2%
(High Growth)
Analyst Spread39.7%
(Moderate)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes PTCT achieves its forward estimates and maintains a stable P/E multiple of 96.4x. This scenario reflects the blended consensus of 26 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
PTCT Price Target Analysis
Updated July 7, 2026As of July 7, 2026, PTC Therapeutics, Inc. (PTCT) has a Wall Street consensus price target of $95.83, based on estimates from 26 covering analysts. With the stock currently trading at $85.44, this represents a potential upside of +12.2%. The company has a market capitalization of $7.09B.
Analyst price targets range from a low of $82.00 to a high of $120.00, representing a 40% spread in expectations. The median target of $90.00 differs from the mean, suggesting potential outlier estimates.
The current analyst consensus rating is Buy, with 17 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, PTCT trades at a trailing P/E of 11.0x and forward P/E of 96.4x. Analysts expect EPS to grow +139.2% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+28.5%
Industry Consensus
Avg Forward P/E
36.0x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SRPTSarepta Therapeutics, Inc. | $2.0B | $19.18 | $25.14 | +31.1% | Buy | 5.4x | 54 |
 BMRNBioMarin Pharmaceutical Inc. | $11.3B | $58.79 | $89.21 | +51.7% | Buy | 11.9x | 41 |
 RAREUltragenyx Pharmaceutical Inc. | $3.3B | $33.70 | $47.11 | +39.8% | Buy | — | 33 |
 ALNYAlnylam Pharmaceuticals, Inc. | $41.8B | $313.04 | $450.64 | +44.0% | Buy | 42.1x | 52 |
 ACADACADIA Pharmaceuticals Inc. | $4.4B | $25.77 | $34.38 | +33.4% | Buy | 67.7x | 37 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 KRYSKrystal Biotech, Inc. | $11.0B | $374.68 | $336.40 | -10.2% | Buy | 48.8x | 17 |
 RYTMRhythm Pharmaceuticals, Inc. | $7.7B | $111.68 | $139.57 | +25.0% | Buy | — | 20 |
 LGNDLigand Pharmaceuticals Incorporated | $6.4B | $320.42 | $265.33 | -17.2% | Buy | 35.4x | 17 |
 PRAXPraxis Precision Medicines, Inc. | $9.1B | $313.50 | $589.00 | +87.9% | Buy | — | 16 |
PTCT — Frequently Asked Questions
Quick answers to the most common questions about buying PTCT stock.
What is the PTCT stock price target for 2026?
PTC Therapeutics, Inc. (PTCT) has a consensus 12-month price target of $95.83, implying 12.2% upside from $85.44. The 26 analysts covering PTCT see moderate appreciation potential.
Is PTCT a buy, sell, or hold?
PTCT has a consensus rating of "Buy" based on 26 Wall Street analysts. The rating breakdown is predominantly bullish, with 17 Buy/Strong Buy ratings. The consensus 12-month price target of $95.83 implies 12.2% upside from current levels.
Is PTCT stock overvalued or undervalued?
At a forward P/E of 96.4334x, PTCT trades at a premium valuation. The consensus price target of $95.83 (12.2% upside) suggests analysts still see growth justifying the multiple.
How high can PTCT stock go?
The most bullish Wall Street analyst has a price target of $120 for PTCT, while the most conservative target is $82. The consensus of $95.83 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover PTCT stock?
PTCT is heavily covered by Wall Street, with 26 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 17 have Buy ratings, 7 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PTCT stock forecast?
The 12-month PTCT stock forecast based on 26 Wall Street analysts shows a consensus price target of $95.83, with estimates ranging from $82 (bear case) to $120 (bull case). The median consensus rating is "Buy".
What is PTCT's forward P/E ratio?
PTCT trades at a forward P/E ratio of 96.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 11.0x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy PTCT stock?
Wall Street analysts are optimistic on PTCT, with a "Buy" consensus rating and $95.83 price target (12.2% upside). 17 of 26 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PTCT price targets vary so much?
PTCT analyst price targets range from $82 to $120, a 40% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $95.83 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare